menù
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Farina Lucia
Main Facility: Haematology
Drug: Venetoclax
Principal Investigator: Prof. De Braud Filippo
Main Facility: Medical Oncology 1
Drug: Paclitaxel + Carboplatino + Pembrolizumab Doxorubicina o Epirubicina + Ciclofosfamide + Pembrolizumab
Main Facility: Thoracic Oncology Unit
Drug: Pembrolizumab, Olomorasib, Pemetrexed, Carboplatino, Cispatino
Principal Investigator: Prof. Corradini Paolo
Drug: Selinexor
Main Facility: Medical Oncology 2
Drug: Trabectedina
Principal Investigator: Dr. Stacchiotti Silvia
Drug: Lurbinectedina e Irinotecan
Principal Investigator: Dr. Gronchi Alessandro
Main Facility: General Surgery 7 – Sarcomas
Drug: Trabectedin combined with radiation therapy.
Principal Investigator: Prof. Mazzaferro Vincenzo
Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation
Drug: Durvalumab E Tremelimumab
Principal Investigator: Dott. Alfieri Salvatore
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: Pembrolizumab
Principal Investigator: Dr. Lo Russo Giuseppe
Drug: R-DXd (raludotatug deruxtecan) I-DXd (ifinatamab deruxtecan) Docetaxel
Drug: Pembrolizumab Mk2870 (sacituzumab tirumotecan) Chemio: Carboplatin, cisplatin, pemetrexed, paclitaxel, gemcitabine (based on squamous or non-squamous histology)
Main Facility: Medical Oncology 1 – Medical Oncology Unit: Melanoma
Drug: Darovasertib, Crizotinib Nivolumab, Ipilimumab, Pembrolizumab, Dacarbazina
Principal Investigator: Prof. Vernieri Claudio
Drug: Atezolizumab
Principal Investigator: Dott.ssa Rusconi Chiara
Drug: Tislelizumab (BGB-A317)
Drug: Pembrolizumab Chemoterapy: -paclitaxel+cisplatin or carboplatin -pemetrexed + cisplatin or carboplatin
Principal Investigator: Dr. Procopio Giuseppe
Main Facility: Genitourinary Medical Oncology
Drug: all drugs in clinical practice group A (dual immunotherapy NIVO + IPI Q4W) group B (immunotherapy + anti-angiogenic)
Drug: Atezolizumab, Futibatinib, Amivantamab
Drug: Patritumab Deruxtecan
Drug: Obinutuzumab
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe